Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGEM Cullinan Therapeutics

Closed 09-09 16:00:00 EDT

21.31

-0.38

-1.75%

盘后21.31

+0.000.00%

19:30 EDT

High21.80	Low21.08	Vol1.28M
Open21.30	D1 Closing21.69	Amplitude3.30%
Mkt Cap1.37B	Tradable Cap1.02B	Total Shares64.35M
T/O27.35M	T/O Rate2.66%	Tradable Shares48.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGEM","market":"US","secType":"STK","nameCN":"Cullinan Therapeutics","latestPrice":21.31,"timestamp":1788984000000,"preClose":21.69,"halted":0,"volume":1278698,"hourTrading":{"tag":"盘后","latestPrice":21.31,"preClose":21.31,"latestTime":"19:30 EDT","volume":15260,"amount":325190.6,"timestamp":1788996606977,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01751959428307988,"floatShares":48082800,"shares":64354694,"eps":-3.468035,"marketStatus":"Closed","change":-0.38,"latestTime":"09-09 16:00:00 EDT","open":21.3,"high":21.795,"low":21.08,"amount":27347641.9958,"amplitude":0.032964,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.468035,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789027200000},"marketStatusCode":5,"adr":0,"listingDate":1610082000000,"exchange":"NASDAQ","adjPreClose":21.69,"preHourTrading":{"tag":"盘前","latestPrice":21.26,"preClose":21.69,"latestTime":"09:29 EDT","volume":1389,"amount":29798.083656,"timestamp":1788960599999,"change":-0.43,"changeRate":-0.019825,"amplitude":0.044721},"postHourTrading":{"tag":"盘后","latestPrice":21.31,"preClose":21.31,"latestTime":"19:30 EDT","volume":15260,"amount":325190.6,"timestamp":1788996606977,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.904989,"impliedVol":1.572,"impliedVolPercentile":0.9402},"requestUrl":"/m/hq/s/CGEM/tweets","defaultTab":"tweets","newsList":[{"id":"2661216312","title":"Why Cullinan Therapeutics (CGEM) Is Up 6.6% After Zipalertinib’s Positive Phase 3 Lung Cancer Data And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2661216312","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661216312?lang=en_us&edition=fundamental","pubTime":"2026-08-22 14:18","pubTimestamp":1787379527,"startTime":"0","endTime":"0","summary":"Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics previously reported that the global Phase 3 REZILIENT3 trial of zipalertinib plus platinum-based chemotherapy in first-line EGFR exon 20 insertion non-small cell lung cancer met its primary endpoint, showing a statistically significant and clinically meaningful progression-free survival benefit with manageable safety.\nThis outcome positions zipalertinib, an investigational next-generation irreversible EGFR inhibitor, as a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgem/cullinan-therapeutics/news/why-cullinan-therapeutics-cgem-is-up-66-after-zipalertinibs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgem/cullinan-therapeutics/news/why-cullinan-therapeutics-cgem-is-up-66-after-zipalertinibs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CHAT","VTHR","AGIX","QTOC","CGEM","ARTY","BK4139","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422315","title":"Cullinan, Taiho say results of Phase 3 trial selected for presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660422315?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:10","pubTimestamp":1787155816,"startTime":"0","endTime":"0","summary":"Taiho Oncology and Cullinan Therapeutics (CGEM) announced that results from the planned interim analysis of the Phase 3 REZILIENT3 trial have been ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-taiho-say-results-of-phase-3-trial-selected-for-presentation-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","CGEM","BBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660444424","title":"Cullinan Says Rezilient3 Interim Data for Zipalertinib Plus Chemotherapy in EGFR Exon 20 NSCLC Lands IASLC WCLC 2026 Presidential Symposium Slot","url":"https://stock-news.laohu8.com/highlight/detail?id=2660444424","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660444424?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:03","pubTimestamp":1787155397,"startTime":"0","endTime":"0","summary":"Cullinan says REZILIENT3 interim data for zipalertinib plus chemotherapy in EGFR exon 20 NSCLC lands IASLC WCLC 2026 Presidential Symposium slotCullinan Therapeutics flagged planned interim results fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL383tKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660543394","title":"UBS Adjusts Cullinan Therapeutics Price Target to $27 From $24, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2660543394","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660543394?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:05","pubTimestamp":1786975559,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics (CGEM) has an average rating of buy and mean price target of $33.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448005","title":"Morgan Stanley Keeps Their Buy Rating on Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448005","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660448005?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:57","pubTimestamp":1786971448,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Cullinan Management, with a price target of $30.00. Accordin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-keeps-their-buy-rating-on-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481022","title":"Cullinan Therapeutics Price Target Maintained with a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481022","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660481022?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:51","pubTimestamp":1786963860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGEM/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660883944","title":"Cullinan Therapeutics price target raised to $47 from $46 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2660883944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660883944?lang=en_us&edition=fundamental","pubTime":"2026-08-17 15:40","pubTimestamp":1786952405,"startTime":"0","endTime":"0","summary":"Clear Street analyst Kaveri Pohlman raised the firm’s price target on Cullinan Therapeutics (CGEM) to $47 from $46 and keeps a Buy rating on the sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-price-target-raised-to-47-from-46-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-price-target-raised-to-47-from-46-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121236","title":"Cullinan Therapeutics CSO Jennifer Michaelson Disposes of 30,000 Common Shares Worth $607,800","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121236","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121236?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:04","pubTimestamp":1786741470,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics CSO Jennifer Michaelson disposes of 30,000 common shares worth $607,800Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson sold 30,000 shares on Aug. 13 at USD 20.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL4xnHYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Cullinan Therapeutics CSO Jennifer Michaelson Disposes of 30,000 Common Shares Worth $607,800","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659119166","title":"U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2659119166","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659119166?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:18","pubTimestamp":1786637899,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-EnerSys, Netflix, SalesforceAugust 13 (Reuters)-The S&P 500 hit an intraday record high on Thursday, boosted by technology stocks, as a drop in crude prices lifted risk ap","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL6N44A14N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYXS","CSCL","DKL","DERM","LNSR","GLNG","LUNR","WSPC","XLC","AKAM","DELL","LESL","BIRK","ARX","FIVE","LUNL","AVAH","RKLX","CRMD","CSCS","DIPR","HLIT","CRM","ENS","TRUM","SPCE","STAA","NEM","TPR","OPEN","CBRS","WQTM","ABEO","RKLB","LWAY","MSGS","OMER","CSCO","MH","HPQ","DIOD","AGMI","OTLK","NFLX","CGEM","IBM","ABCL","STUB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659652951","title":"Cullinan Management (CGEM) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2659652951","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659652951?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:36","pubTimestamp":1786635371,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Cullinan Management today and set a price target of $28.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cullinan-management-cgem-receives-a-rating-update-from-a-top-analyst-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cullinan-management-cgem-receives-a-rating-update-from-a-top-analyst-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659150678","title":"Cullinan Therapeutics Shares Reverse Premarket Course; Last Down 4.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659150678?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:39","pubTimestamp":1786628388,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A1JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659574871","title":"Sector Update: Healthcare Stocks Advance Pre-Bell Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2659574871","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659574871?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:13","pubTimestamp":1786626787,"startTime":"0","endTime":"0","summary":"Healthcare stocks were advancing pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF  up 0.3% and the iShares Biotechnology ETF  0.6% higher.MeiraGTx  shares were up more than 7% after the company reported that it swung to a Q2 net income as revenue surged during the period.Cullinan Therapeutics , Taiho Oncology and Taiho Pharmaceutical said a phase 3 clinical trial evaluating the combination of their jointly developed drug zipalertinib and chemotherapy as a first-line treatment for adults with previously untreated, locally advanced or metastatic non-small cell lung cancer met its primary endpoint of progression-free survival. Shares of Cullinan Therapeutics were up more than 7% premarket.Ascendis Pharma  stock was up more than 1% after the company posted higher Q2 non-IFRS earnings and revenue.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XBI","LU0889565916.HKD","ASND","BK4137","LU0109394709.USD","LU0128526141.USD","BK4588","BK4585","IBB","XLV","MGTX","HCSG","BK4139","LU0029874061.USD","LU0320765992.SGD","CGEM","BK4581","LABU","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659170157","title":"Cullinan Therapeutics Price Target Raised to $42.00/Share from $39.00 by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2659170157","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659170157?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:12","pubTimestamp":1786626720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGEM/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151594","title":"Wedbush Adjusts PT on Cullinan Therapeutics to $42 From $39, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151594","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151594?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:45","pubTimestamp":1786621529,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics (CGEM) has an average rating of buy and mean price target of $33.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659215339","title":"Cullinan Therapeutics Shares Rise 12.3% Premarket After Lung Cancer Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2659215339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659215339?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:13","pubTimestamp":1786615988,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A0MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659215879","title":"Cullinan Therapeutics, - Zipalertinib Arm Shows Significant Improvement in Progression-Free Survival with Manageable Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2659215879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659215879?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:04","pubTimestamp":1786615458,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A0MN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659158790","title":"Cullinan Therapeutics, - Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659158790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659158790?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:04","pubTimestamp":1786615458,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A0MN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659158713","title":"Cullinan Therapeutics, - Taiho Oncology, Taiho Pharmaceutical, Cullinan Therapeutics to Pursue U.S. Regulatory Approval for Zipalertinib Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2659158713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659158713?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:04","pubTimestamp":1786615458,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A0MN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659130742","title":"Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2659130742","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659130742?lang=en_us&edition=fundamental","pubTime":"2026-08-13 17:39","pubTimestamp":1786613984,"startTime":"0","endTime":"0","summary":"BUZZ-Cullinan climbs as lung cancer drug meets late-stage trial goal** Shares of Cullinan TherapeuticsCGEM.Orise 6% to $20.77 premarket** Cullinan says its experimental cancer drug, zipalertinib, when","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4N44A0QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BK4139","LU0109394709.USD","LU0320765992.SGD","PTH","CGEM","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IDNA","IE00B2B36J28.USD","IE0009355771.USD","CANC","RVMD","IE0009354923.USD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659189846","title":"Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint in Planned Interim Analysis of Phase 3 Rezilient3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659189846","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659189846?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:32","pubTimestamp":1786577526,"startTime":"0","endTime":"0","summary":"BRIEF-Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint In Planned Interim Analysis Of Phase 3 Rezilient3 TrialAug 13 (Reuters)-Otsuka Holdings Co., Ltd.4578.T:OTSU","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cullinantherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":0.2234},{"period":"3month","weight":0.8},{"period":"6month","weight":0.5548},{"period":"1year","weight":2.1711},{"period":"ytd","weight":1.0957}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.0094},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.15},{"period":"1year","weight":0.1805},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.097052},{"month":2,"riseRate":0.666667,"avgChangeRate":0.069507},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.100308},{"month":4,"riseRate":0.333333,"avgChangeRate":0.044053},{"month":5,"riseRate":0.666667,"avgChangeRate":0.039338},{"month":6,"riseRate":0.5,"avgChangeRate":-0.027852},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004001},{"month":8,"riseRate":0.5,"avgChangeRate":0.087786},{"month":9,"riseRate":0,"avgChangeRate":-0.12524},{"month":10,"riseRate":0.6,"avgChangeRate":0.085935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.037651},{"month":12,"riseRate":0.2,"avgChangeRate":-0.046792}],"exchange":"NASDAQ","name":"Cullinan Therapeutics","nameEN":"Cullinan Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cullinan Therapeutics(CGEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cullinan Therapeutics,CGEM,Cullinan Therapeutics股票,Cullinan Therapeutics股票老虎,Cullinan Therapeutics股票老虎国际,Cullinan Therapeutics行情,Cullinan Therapeutics股票行情,Cullinan Therapeutics股价,Cullinan Therapeutics股市,Cullinan Therapeutics股票价格,Cullinan Therapeutics股票交易,Cullinan Therapeutics股票购买,Cullinan Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cullinan Therapeutics(CGEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction